These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 24692602)

  • 1. Further evidence for influenza and pneumococcal vaccination in patients treated with disease modifying antirheumatic drugs and anti-tumor necrosis factor agents.
    Kapetanovic MC
    J Rheumatol; 2014 Apr; 41(4):626-8. PubMed ID: 24692602
    [No Abstract]   [Full Text] [Related]  

  • 2. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.
    Kivitz AJ; Schechtman J; Texter M; Fichtner A; de Longueville M; Chartash EK
    J Rheumatol; 2014 Apr; 41(4):648-57. PubMed ID: 24584918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Certolizumab for rheumatoid arthritis.
    Markatseli TE; Papagoras C; Nikoli A; Voulgari PV; Drosos AA
    Clin Exp Rheumatol; 2014; 32(3):415-23. PubMed ID: 24447441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Letter: Effectiveness of split-dose certolizumab pegol for Crohn's disease.
    Kane SV; Neis B; Becker BD; Bruining D; Faubion WA; Kisiel J; Loftus EV; Pardi D; Raffals L; Schroeder K; Tremaine WJ
    Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1412. PubMed ID: 24206378
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug-induced erythema nodosum after the administration of certolizumab in Crohn's disease.
    Biedermann L; Kerl K; Rogler G; Hofbauer GF
    Inflamm Bowel Dis; 2013 Jan; 19(1):E4-6. PubMed ID: 22127817
    [No Abstract]   [Full Text] [Related]  

  • 6. Interstitial lung disease following certolizumab pegol.
    Pearce F; Johnson SR; Courtney P
    Rheumatology (Oxford); 2012 Mar; 51(3):578-80. PubMed ID: 22116998
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How FABulous is PEGgy? Certoliziumab pegol from the bench to the patients.
    Aletaha D
    BioDrugs; 2014 Apr; 28 Suppl 1():S3-4. PubMed ID: 24687233
    [No Abstract]   [Full Text] [Related]  

  • 9. Certolizumab pegol (Cimzia) and ustekinumab (Stelara) for psoriatic arthritis.
    Med Lett Drugs Ther; 2014 Feb; 56(1435):10-2. PubMed ID: 24662976
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting nanomedicines in the treatment of rheumatoid arthritis: focus on certolizumab pegol.
    Barnes T; Moots R
    Int J Nanomedicine; 2007; 2(1):3-7. PubMed ID: 17722505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice.
    Punzi L; Lapadula G; Mathieu A
    BioDrugs; 2014 Apr; 28 Suppl 1():S25-37. PubMed ID: 24687236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prevention of influenza and pneumococci should be standard. Vaccination plan for rheumatic patients].
    MMW Fortschr Med; 2008 Oct; 150(44):12-3. PubMed ID: 19024485
    [No Abstract]   [Full Text] [Related]  

  • 13. Blaschkitis under certolizumab for rheumatoid arthritis.
    Couderc M; Soubrier M
    Joint Bone Spine; 2014 Jul; 81(4):372-3. PubMed ID: 24439961
    [No Abstract]   [Full Text] [Related]  

  • 14. [Certolizumab pegol].
    Delgado Frías E; Díaz González JF
    Reumatol Clin; 2011 Mar; 6S3():S7-11. PubMed ID: 21794764
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New tumour necrosis factor inhibitors for rheumatoid arthritis: are there benefits from extending choice?
    Scott DL; Cope A
    Ann Rheum Dis; 2009 Jun; 68(6):767-9. PubMed ID: 19435722
    [No Abstract]   [Full Text] [Related]  

  • 16. Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study.
    Tanaka Y; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Eguchi K; Watanabe A; Origasa H; Shoji T; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Sep; 24(5):725-33. PubMed ID: 24372225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic agents in rheumatology: act II.
    Kavanaugh A
    Clin Exp Rheumatol; 2010; 28(3 Suppl 59):S2-4. PubMed ID: 20576218
    [No Abstract]   [Full Text] [Related]  

  • 18. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
    Meroni PL; Valesini G
    BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracranial hemorrhage and extensive cerebral venous thrombosis associated with ulcerative colitis.
    Adrish M; Rios R
    Can J Gastroenterol Hepatol; 2014 Jun; 28(6):299-300. PubMed ID: 24945182
    [No Abstract]   [Full Text] [Related]  

  • 20. Novel TNF antagonists for the treatment of rheumatoid arthritis.
    Statkute L; Ruderman EM
    Expert Opin Investig Drugs; 2010 Jan; 19(1):105-15. PubMed ID: 20001558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.